Argos Says FDA Willing To ADAPT To Longer Follow-Up For Immunotherapy
Executive Summary
Argos Therapeutics reports FDA support for its plan to continue its ADAPT trial of rocapuldencel-T for metastatic renal cell carcinoma despite a futility finding by the independent data monitoring committee.